KET-MCI: An Open-label Trial of Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment
Phase: PHASE2 | Sponsor: Icahn School of Medicine at Mount Sinai | Compound: Ketamine
- Status
- active
- Institution
- Icahn School of Medicine at Mount Sinai
- Start date
- 2024-11-01
- End date
- 2025-09-01
- Registry ID
- NCT06069843
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.